Intec Pharma Expands Intellectual Property With a New

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Intec Pharma Expands Intellectual Property With a New Patent for the Accordion Pill in Europe

JERUSALEM, ISRAEL--(Marketwired - Oct 22, 2015) -  Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed by the European Patent Office (EPO) that a European patent will be granted November 4, 2015 on the Company's European Patent Application for a "Method and Apparatus for Forming Delivery Devices for Oral Intake of an Agent."

The patent, number EP 1981465, protects a method of producing Intec's Accordion Pill platform, and the Accordion Pill produced thereby. The platform may be made from any suitable substances, and is intended for oral delivery of any pharmaceutically active agent of interest. The patent is currently scheduled to remain in force until January 18, 2027.

Zeev Weiss, CEO of Intec Pharma, said: "The new patent in Europe is an important addition to our IP portfolio, and joins already granted patents of the same IP family in the United States and other countries. The Accordion Pill IP protection is very important for pharmaceutical companies, when considering this platform technology for the life cycle management of their drugs, as well as for the protection of our own pipeline products." 

About Intec Pharma Ltd.

Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline currently includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CDLD, is being developed for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and Accordion Pill Zaleplon, or AP-ZP, is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements involve certain risks and uncertainties, including, among others, risks impacting the ability of the Company to complete any public offering of its securities because of general market conditions or other factors and risks that could cause the Company's results to differ materially from those expected by Company management. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, and include the following: the company's ability to develop and commercialize its product candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company's clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company's hormone therapy drug candidates; the availability of reimbursement from government authorities and health insurance companies for the company's products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.

Contacts: Zeev Weiss Chief Executive Officer (+972) (2) 586-4657 Zeev@intecpharma.com PCG Advisory Investors: Vivian Cervantes Managing Director Phone (+1) 212 554-5482 Media Sean Leous Managing Director Phone (+1) 646 863-8998

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 334

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 423

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 256

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 301

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 448

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 215

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 349

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 245

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 285

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 412

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

TransAlta Announces Right to Convert Series G Preferred Shares

Updated Category News Views 124

Update on TransAlta's Series G Preferred Shares TransAlta Corporation (TSX: TA; NYSE: TAC) has shared important news about its cumulative redeemable rate reset first preferred shares, known as Series G. The company has decided not to exercise its right to redeem these shares on the upcoming conversion date. Details on the Conversion of Series G Shares Holders of Series G...

Continue Reading
Automotive Engine Oil Market Surge: Innovations and Challenges

Updated Category News Views 469

The Rising Tide of the Automotive Engine Oil Market The global automotive engine oil market is on a exciting trajectory, projected to grow significantly in the coming years. This growth can largely be attributed to the increasing number of vehicles on the roads and advancements in engine oil technology. Experts estimate that the market will grow by approximately USD 12.5...

Continue Reading
Understanding Ferguson Enterprises' Price-to-Earnings Ratio

Updated Category News Views 112

Ferguson Enterprises Inc. Recent Stock Performance As we delve into Ferguson Enterprises Inc. (NYSE: FERG), the current trading price stands at $227.06, reflecting a slight decrease of 0.71%. In the preceding month, the stock has experienced a drop of 10.00%. However, when we take a year-long view, it’s noteworthy that the stock has actually appreciated by 30.82%. This...

Continue Reading
Cyabra to Engage in Needham Growth Conference: What to Expect

Updated Category News Views 100

Cyabra to Engage in Needham Growth Conference Cyabra Ltd., a pioneering AI platform focused on the detection of real-time disinformation, is set to participate in an influential industry event: the 27th Annual Needham Growth Conference. This virtual conference presents an exciting opportunity for investors and stakeholders to connect with Cyabra's leadership, specifically...

Continue Reading
Job Market Frustrations: The Truth Behind 'Remote Work' Claims

Updated Category News Views 451

Job Seekers Faces Misleading Remote Work Claims Recently, stories shared online illustrate a frustrating trend in the job market, particularly concerning remote work commitments. Job seekers are collectively expressing outrage over interviews that promise flexible arrangements only to reveal hidden requirements for in-office presence. This alarming shift has spurr

Continue Reading